San Diego-based Fate Therapeutics announced this morning that it has named Christian Weyer, M.D., M.A.S., as its new President and CEO. Weyer joins the firm from Amylin Pharmaceuticals. Weyer had been serving as SVP Research and Development at Amylin when it was acquired by Bristol-Myers Squibb. Weyer takes oer for William H. Rastetter, who was serving as interim CEO; Rastetter is a partner at Venrock, and continues as Chairman of the company's board. Fate Therapeutics is working on stem cell therapy products.